Forbedringen i progressionsfri overlevelse (PFS) og responsraten er kun forbundet med en vis yderligere, let kontrollerbar toksicitet, hvilket giver et gunstigt risk/ benefit- forhold.
This improvement in PFS and response rate is only associated with some additional, readily manageable toxicity, resulting in a favourable risk benefit profile.